User profiles for Joe Zhou

Joseph Xu Zhou

Institute for systems biology
Verified email at systemsbiology.org
Cited by 2472

[PDF][PDF] TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator

…, B Hu, JS Hong, JW Perry, SF Chen, JXH Zhou… - Immunity, 2002 - cell.com
DR3 is a death domain-containing receptor that is upregulated during T cell activation and
whose overexpression induces apoptosis and NF-κB activation in cell lines. Here we show …

First demonstration of amplification at 1 THz using 25-nm InP high electron mobility transistor process

…, W Yoshida, M Lange, J Lee, J Zhou… - IEEE Electron …, 2015 - ieeexplore.ieee.org
We report the first ever terahertz monolithic integrated circuit amplifier based on 25-nm InP
high electron mobility transistor (HEMT) process demonstrating amplification at 1 THz (1000 …

Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-α fusion protein in cynomolgus monkeys

…, HS Olsen, B Nardelli, JH Murray, JXH Zhou… - … of Pharmacology and …, 2002 - ASPET
Interferon-α (IFN-α) is indicated for the treatment of certain viral infections including hepatitis
B and C, and cancers such as melanoma. The short circulating half-life of unmodified IFN-α …

Strategic alliance-based sourcing and market performance: evidence from foreign firms operating in China

JY Murray, M Kotabe, JN Zhou - The Future of Global Business, 2011 - taylorfrancis.com
One of the most important trends in industrial buying behavior is the radical change in buying
attitudes and behavior among business customers. Many firms are consolidating their …

Flowability of moist pharmaceutical powders

E Emery, J Oliver, T Pugsley, J Sharma, J Zhou - Powder Technology, 2009 - Elsevier
The effect of moisture content on four pharmaceutical powders (an active pharmaceutical
ingredient (API), Aspartame, Hydroxypropyl Methylcellulose (HPMC), and Respitose ML001) …

Basic concepts in Q membrane chromatography for large‐scale antibody production

JX Zhou, T Tressel - Biotechnology progress, 2006 - Wiley Online Library
The large‐scale production of recombinant human monoclonal antibodies demands
economical purification processes with high throughputs. In this article we briefly describe a …

In silico selection of therapeutic antibodies for development: viscosity, clearance, and chemical stability

…, RF Kelley, I Chorny, JZ Zhou… - Proceedings of the …, 2014 - National Acad Sciences
For mAbs to be viable therapeutics, they must be formulated to have low viscosity, be
chemically stable, and have normal in vivo clearance rates. We explored these properties by …

A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models

…, J Kendrew, C Reimer, S Wen, JQ Zhou… - Molecular cancer …, 2010 - AACR
Localized angiopoietin-2 (Ang2) expression has been shown to function as a key regulator
of blood vessel remodeling and tumor angiogenesis, making it an attractive candidate for …

Autonomous battery swapping system for quadcopter

D Lee, J Zhou, WT Lin - 2015 international conference on …, 2015 - ieeexplore.ieee.org
Multicopters drain much energy from the battery because of on-board avionics system and
other devices. Limited by the battery capacity, missions that require longer flight time cannot …

[HTML][HTML] Cell fate decision as high-dimensional critical state transition

M Mojtahedi, A Skupin, J Zhou, IG Castaño… - PLoS …, 2016 - journals.plos.org
Cell fate choice and commitment of multipotent progenitor cells to a differentiated lineage
requires broad changes of their gene expression profile. But how progenitor cells overcome …